Citations

Clear

6274 citation(s) found for "To, Andrew".

Changes in Abdominal Aortic Aneurysm Size after Endovascular Repair with Zenith, AneuRx, and Custom-made Stent-Grafts
Neuhauser, Beate, Oldenburg, W. Andrew, Hakaim, Albert G.

Mayo Clinic

The American Surgeon | November 28, 2022 | Volume: 70 | Issue: 7 | Pages: 630-634

10.1177/000313480407000714 Get It

The aim of this study was to determine the maximal aneurysm diameter (MAD), the total aneurysm volume (TAV), the intra-aneurysm vascular channel (IAVC), and total thrombus volume (TTV) and compare changes in those parameters during a 12-month time period. In addition, these parameters for three different endovascular grafts were compared. A retrospective review of 42 patients who had undergone endovascular aneurysm repair (EVAR) between July 1999 and March 2001, and without evidence of an endoleak or migration, was performed. The minimum follow-up in this group was 12 months. The three grafts deployed were Dacron-stainless steel bifurcated grafts with suprarenal fixation [Zenith; Cook, Inc. ( n = 14)], Dacron stainless steel aorto uni-iliac grafts with suprarenal fixation [custom-made ( n = 10)], and externally supported Dacron nitinol bifurcated grafts [AneuRx; Medtronic, Inc. ( n = 18)]. Volumetric measurements were obtained from CT images performed preoperatively, at 1 month and 12 months thereafter, using a 3-D Magicview 1000 workstation (Siemens, Inc.). Regardless of the type of endograft, a significant Change in MAD and TAV ( P = 0.008), IAVC ( P = 0.031), and TTV ( P = 0.001) was observed over the 12-month postoperative period. Both maximum diameter and total aneurysm volume appear to reflect accurately successful aneurysm exclusion. We conclude that both two-dimensional, maximal aneurysm diameter and three-dimensional, total aneurysm volume accurately reflect changes in morphology after endovascular aneurysm repair.
Metastatic Thyroid Carcinoma to the Kidneys Presenting Initially as Bilateral Renal Masses: A Rare Case Report and Literature Review
Youssef, Bahaaldin, Hanna, Karina, Ardor, Gokce Deniz , Alhaj, Ahmed M., Nassar, Aziza , Bowman, Andrew, Nassar, Aziza , Bowman, Andrew W.

Mayo Clinic

International Journal of Surgical Pathology | November 28, 2022 | Volume: 31 | Issue: 5 | Pages: 795-800

10.1177/10668969221138860 | PMID 36437643 Get It

Thyroid cancers exist in multiple forms. Papillary and follicular carcinomas of the thyroid are often referred to as well-differentiated thyroid cancers. Well-differentiated thyroid cancers rarely present as a distant metastatic cancer on initial diagnosis. Papillary thyroid cancer tends to have a good prognosis; however, if distant metastasis of PTC is present, there is usually a poor clinical outcome with a less favorable prognosis. In this study, we report a 90-year-old female who presented with right-sided abdominal discomfort. A renal ultrasound revealed bilateral upper pole renal masses. A percutaneous biopsy was ordered, and the microscopic examination revealed bilateral renal metastasis with a follicular variant of papillary thyroid carcinoma. The patient underwent thyroidectomy and sustained radiation therapy for her bilateral renal metastases. She died 6 years after her initial diagnosis, due to sepsis. This is the second study in literature to report bilateral renal metastasis of follicular variant of papillary thyroid cancer.
Body mass index and molecular subtypes of colorectal cancer
Murphy, Neil , Newton, Christina C. , Papadimitriou, Nikos , Hoffmeister, Michael , Phipps, Amanda I. , Harrison, Tabitha A. , Aglago, Elom K. , Berndt, Sonja I. , Brenner, Hermann , Cao, Yin , Chang‐Claude, Jenny , French, Amy J. , Gallinger, Steven , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B. , Harlid, Sophia , Huang, Wen‐Yi , Laskar, Ruhina Shirin , Mandic, Marko , Nowak, Johnathan A., Obón‐Santacana, Mireia , Steinfelder, Robert S. , Thibodeau, Stephen N. , Trinh, Quang M. , Tsilidis, Kostas K, Guelpen, Bethany Van , Wang, Xiaoliang , Woods, Michael O. , Zaidi, Syed Hassan Ejaz , Gunter, Marc J. , Peters, Ulrike , Song, Mingyang , Song, Mingyang , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann , Cao, Yin , Chen, Xuechen , Drew, David A , Harlid, Sophia , Huang, Wen-Yi , Marchand, Loïc Le , Limburg, Paul, Sun, Wei , Ugai, Tomotaka , Van Guelpen, Bethany , Wang, Xiaoliang , Woods, Michael O , Gunter, Marc J , Murphy, Neil , Song, Mingyang , Aglago, Elom K , Obón-Santacana, Mireia , Papadimitriou, Nikos , Mandic, Marko , Trinh, Quang M , Georgeson, Peter , Newcomb, Polly A. , Buchanan, Daniel D. , Chan, Andrew T. , Cheng, Iona C. , Dimou, Niki , Drew, David A. , Farris, Alton B. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Marchand, Loı̈c Le , Limburg, Paul J. , Lin, Yi , Ogino, Shuji , Qu, Conghui , Sakoda, Lori C. , Schoen, Robert E. , Southey, Melissa C. , Stadler, Zsofia , Sun, Wei , Toland, Amanda Ewart , Tsilidis, Kostas K, Campbell, Peter T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 26, 2022 | Volume: 115 | Issue: 2 | Pages: 165-173

10.1093/jnci/djac215 | PMID 36445035 Get It

Abstract Background Obesity is an established risk factor for colorectal cancer (CRC), but the evidence for the association is inconsistent across molecular subtypes of the disease. Methods We pooled data on body mass index (BMI), tumor microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, and Jass classification types for 11 872 CRC cases and 11 013 controls from 11 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) adjusted for covariables. Results Higher BMI was associated with increased CRC risk (OR per 5 kg/m2 = 1.18, 95% CI = 1.15 to 1.22). The positive association was stronger for men than women but similar across tumor subtypes defined by individual molecular markers. In analyses by Jass type, higher BMI was associated with elevated CRC risk for types 1-4 cases but not for type 5 CRC cases (considered familial-like/Lynch syndrome microsatellite instability-H, CpG island methylator phenotype-low or negative, BRAF-wild type, KRAS-wild type, OR = 1.04, 95% CI = 0.90 to 1.20). This pattern of associations for BMI and Jass types was consistent by sex and design of contributing studies (cohort or case-control). Conclusions In contrast to previous reports with fewer study participants, we found limited evidence of heterogeneity for the association between BMI and CRC risk according to molecular subtype, suggesting that obesity influences nearly all major pathways involved in colorectal carcinogenesis. The null association observed for the Jass type 5 suggests that BMI is not a risk factor for the development of CRC for individuals with Lynch syndrome.
Metastatic melanoma involving a genetically confirmed angiofibroma of soft tissue: A previously unreported type of tumor‐to‐tumor metastasis
Short, Emma , Logan, Suzanna , Thangaiah, Judith Jebastin, Folpe, Andrew L. , Short, Emma L , Logan, Suzanna J

Mayo Clinic

Journal of Cutaneous Pathology | November 26, 2022 | Volume: 50 | Issue: 3 | Pages: 220-222

10.1111/cup.14366 | PMID 36428265 Get It

AbstractTumor‐to‐tumor metastases are an uncommon phenomenon and are very rare in the context of malignant melanoma. This case report describes a 73‐year‐old male who underwent an excision of a melanoma from his forehead. Six months later, he developed metastatic disease, including metastasis to a genetically confirmed angiofibroma of soft tissue of the abdominal wall. Angiofibroma of soft tissue is a relatively recently described benign fibrovascular soft tissue tumor, and there appear to be no previous reports of it being a recipient tumor for a metastasis. Awareness of the phenomenon of tumor‐to‐tumor metastasis and of the distinctive morphologic and molecular genetic features of angiofibroma are critical to avoid misdiagnosis of this very rare event as “dedifferentiated” melanoma.
A practical guide to the development and deployment of deep learning models for the Orthopedic surgeon: part I
Nwachukwu, Benedict U. , Martin, R. Kyle , Kelly, Bryan T. , Pearle, Andrew D. , Pareek, Ayoosh , Oeding, Jacob F. , Williams, Riley J. , Karlsson, Jón , Camp, Christopher L. , Ranawat, Anil S.

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | November 25, 2022 | Volume: 31 | Issue: 2 | Pages: 382-389

10.1007/s00167-022-07239-1 | PMID 36427077 Get It

AbstractDeep learning has a profound impact on daily life. As Orthopedics makes use of this rapid escalation in technology, Orthopedic surgeons will need to take leadership roles on deep learning projects. Moreover, surgeons must possess an understanding of what is necessary to design and implement deep learning‐based project pipelines. This review provides a practical guide for the Orthopedic surgeon to understand the steps needed to design, develop, and deploy a deep learning pipeline for clinical applications. A detailed description of the processes involved in defining the problem, building the team, acquiring and curating the data, labeling the data, establishing the ground truth, pre‐processing and augmenting the data, and selecting the required hardware is provided. In addition, an overview of unique considerations involved in the training and evaluation of deep learning models is provided. This review strives to provide surgeons with the groundwork needed to identify gaps in the clinical landscape that deep learning models may be able to fill and equips them with the knowledge needed to lead an interdisciplinary team through the process of creating novel deep‐learning‐based solutions to fill those gaps.
Development and application of a computable genotype model in the GA4GH Variation Representation Specification
Goar, Wesley , Babb, Lawrence , Cline, Melissa , Kuzma, Kori , Lee, Jennifer , Nelson, Tristan , Smith, Anastasia , Stahl, Kathryn , Bratulin, Anastasia L. , Babb, Lawrence , Chamala, Srikar , Freimuth, Robert R. , Hart, Reece K. , Prlić, Andreas , Riehle, Kevin P. , Yates, Andrew , Rehm, Heidi L. , Wagner, Alex H.

Mayo Clinic

Biocomputing 2023 | November 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: 383-394

10.1142/9789811270611_0035 Get It

Pulsatile Pressure Delivery of Continuous-Flow Left Ventricular Assist Devices Is Markedly Reduced Relative to Heart Failure Patients
Rosenbaum, Andrew , Rossman, Timothy, Reddy, Yogesh N.V. , Villavicencio, Mauricio A. , Stulak, John M., Spencer, Philip J. , Kushwaha, Sudhir S. , Behfar, Atta , Rosenbaum, Andrew N , Rossman, Timothy L, Nishimura, Rick , Behfar, Atta , Kushwaha, Sudhir

Mayo Clinic

ASAIO Journal | November 23, 2022 | Volume: 69 | Issue: 5 | Pages: 445-450

10.1097/mat.0000000000001859 | PMID 36417497 Get It

Although continuous-flow left ventricular assist devices (CF-LVADs) provide an augmentation in systemic perfusion, there is a scarcity of in vivo data regarding systemic pulsatility on support. Patients supported on CF-LVAD therapy (n = 71) who underwent combined left/right catheterization ramp study were included. Aortic pulsatility was defined by the pulsatile power index (PPI), which was also calculated in a cohort of high-output heart failure (HOHF, n = 66) and standard HF cohort (n = 44). PPI was drastically lower in CF-LVAD–supported patients with median PPI of 0.006 (interquartile range [IQR], 0.002–0.012) compared with PPI in the HF population at 0.09 (IQR, 0.06–0.17) or HOHF population at 0.25 (IQR, 0.13–0.37; p < 0.0001 among groups). With speed augmentation during ramp, PPI values fell quickly in patients with higher PPI at baseline. PPI correlated poorly with left ventricular ejection fraction (LVEF) in all groups. In CF-LVAD patients, there was a stronger correlation with LV dP/dt (r = 0.41; p = 0.001) than LVEF (r = 0.21; p = 0.08; p int < 0.001). CF-LVAD support is associated with a dramatic reduction in arterial pulsatility as measured by PPI relative to HOHF and HF cohorts and decreases with speed. Further work is needed to determine the applicability to the next generation of device therapy.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Sonneveld, Pieter , Chanan‐Khan, Asher , Nooka, Ajay K. , Beksaç, Meral , Hungria, Vânia , Munder, Markus , Mateos, María‐Victoria , Ahmadi, Tahamtan , Qin, Xiang , Mayo, Wendy Garvin, Gai, Xue , Carey, Jodi, Carson, Robin, Spencer, Andrew , Nooka, Ajay K , Masszi, Tamas , Beksac, Meral , Hungria, Vania , Munder, Markus , Mateos, María-Victoria , Mark, Tomer M , Levin, Mark-David , Gai, Xue , Spencer, Andrew , Weisel, Katja C , Masszi, Tamás , Špıčka, Ivan

Mayo Clinic

Journal of Clinical Oncology | November 22, 2022 | Volume: 41 | Issue: 8 | Pages: 1600-1609

10.1200/jco.21.02734 | PMID 36413710 Get It

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).
Great Toe Transplantation
Forte, Antonio J. , Maita, Karla C. , Safa, Bauback , Buncke, Gregory M. , Buntic, Rudolph, Watt, Andrew, Torres-Guzman, Ricardo A, Forte, Antonio Jorge , Torres‐Guzman, Ricardo A. , Ávila, Francisco R. , Watt, Andrew

Mayo Clinic

Seminars in Plastic Surgery | November 22, 2022 | Volume: 36 | Issue: 04 | Pages: 243-252

10.1055/s-0042-1758689 | PMID 36561428 Get It

AbstractDespite being relatively uncommon in the general population, thumb amputations cause severe disability. More than 3,300 thumb amputations occurred in the United States. The thumb makes up around 40% of the function of the hand. Therefore, losing it would result in significant medical, hospital, and societal costs. Thumb reconstruction surgery's primary goal is to restore grip strength, including the range of motion, fine and tripod pinch, power grasp, strength, and sensibility, while secondary goals include restoring hand aesthetics. In cases of thumb replantation, like-for-like replacement is possible; however, when thumb replantation is not possible, great toe-to-hand transplantation is the best available reconstruction. When compared with other reconstructive options such as osteoplastic thumb reconstruction, pollicization, second toe transplantation, and the use of a thumb prosthesis, great toe transplantation provides superior function and aesthetics. For restoring pinch, sensitivity, strength, and aesthetics of the hand with well-tolerated donor site morbidity, toe to thumb transplantation is regarded as the gold standard.
Cardiovascular/Stroke Risk Stratification in Diabetic Foot Infection Patients Using Deep Learning-Based Artificial Intelligence: An Investigative Study
Khanna, Narendra N. , Maindarkar, Mahesh , Viswanathan, Vijay , Puvvula, Anudeep , Paul, Sudip , Bhagawati, Mrinalini , Ahluwalia, Puneet , Ruzsa, Zoltán , Krishnan, Padukone R., Singh, Inder M. , Laird, John R. , Fatemi, Mostafa , Dhanjil, Surinder, Saba, Luca , Balestrieri, Antonella , Faa, Gavino , Paraskevas, Kosmas I. , Misra, Durga Prasanna , Agarwal, Vikas , Sharma, Aman , Teji, Jagjit S. , Al-Maini, Mustafa , Nicolaides, Andrew , Rathore, Vijay , Naidu, Subbaram, Liblik, Kiera , Johri, Amer M. , Turk, Monika, Sobel, David , Miner, Martin , Višković, Klaudija , Tsoulfas, George, Protogerou, Athanase D. , Mavrogeni, Sophie , Fouda, Mostafa M. , Suri, Jasjit S. , Maindarkar, Mahesh A , Fatemi, Mostafa , Faa, Gavino , Misra, Durga Prasanna , Agarwal, Vikas , Nicolaides, Andrew , Naidu, Subbaram , Sobel, David W , Viskovic, Klaudija , Tsoulfas, George , Protogerou, Athanasios , Mavrogeni, Sophie , Fouda, Mostafa M , Ruzsa, Zoltan , Paraskevas, Kosmas I , Paul, Sudip , Bhagawati, Mrinalini , Sharma, Aditya , Kolluri, Raghu , Alizad, Azra , Saba, Luca , Kitas, George D. , Kalra, Mannudeep K. , Suri, Jasjit S.

Mayo Clinic

Journal of Clinical Medicine | November 21, 2022 | Volume: 11 | Issue: 22 | Pages: 6844

10.3390/jcm11226844 | PMID 36431321 Get It

A diabetic foot infection (DFI) is among the most serious, incurable, and costly to treat conditions. The presence of a DFI renders machine learning (ML) systems extremely nonlinear, posing difficulties in CVD/stroke risk stratification. In addition, there is a limited number of well-explained ML paradigms due to comorbidity, sample size limits, and weak scientific and clinical validation methodologies. Deep neural networks (DNN) are potent machines for learning that generalize nonlinear situations. The objective of this article is to propose a novel investigation of deep learning (DL) solutions for predicting CVD/stroke risk in DFI patients. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) search strategy was used for the selection of 207 studies. We hypothesize that a DFI is responsible for increased morbidity and mortality due to the worsening of atherosclerotic disease and affecting coronary artery disease (CAD). Since surrogate biomarkers for CAD, such as carotid artery disease, can be used for monitoring CVD, we can thus use a DL-based model, namely, Long Short-Term Memory (LSTM) and Recurrent Neural Networks (RNN) for CVD/stroke risk prediction in DFI patients, which combines covariates such as office and laboratory-based biomarkers, carotid ultrasound image phenotype (CUSIP) lesions, along with the DFI severity. We confirmed the viability of CVD/stroke risk stratification in the DFI patients. Strong designs were found in the research of the DL architectures for CVD/stroke risk stratification. Finally, we analyzed the AI bias and proposed strategies for the early diagnosis of CVD/stroke in DFI patients. Since DFI patients have an aggressive atherosclerotic disease, leading to prominent CVD/stroke risk, we, therefore, conclude that the DL paradigm is very effective for predicting the risk of CVD/stroke in DFI patients.